Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting cancer through simultaneous inhibition of key metabolic enzymes

ABSTRACT: Targeting cancer through simultaneous inhibition of key metabolic enzymes

PROVIDER: PRJNA1205711 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31872623_1.fastq.gz	Fastqsanger.gz
	SRR31872623_2.fastq.gz	Fastqsanger.gz
	SRR31872624_1.fastq.gz	Fastqsanger.gz
	SRR31872624_2.fastq.gz	Fastqsanger.gz
	SRR31872625_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 36

Similar Datasets

Targeting cancer through simultaneous inhibition of key metabolic enzymes

Project description:This study explored the potential metabolic vulnerabilities of ovarian cancer cells in comparison to their non-oncogenically transformed precursor cells. A synthetic lethal screen with inhibitors of metabolic pathways showed that simultaneous administration of (R)-GNE-140 and BMS-986205 (Linrodostat) preferentially halted proliferation of tumor cells. While (R)-GNE-140 inhibits lactate dehydrogenase (LDH)A/B and thus effective glycolysis, the BMS-986205 compound, in addition to its known inhibitory activity on Indoleamine 2,3-dioxygenase (IDO1), can also restrict oxidative phosphorylation, as revealed in this study. BMS-986205, which is already in multiple phase III clinical trials, inhibits the Q site of complex I and thus ATP production through mitochondrial respiration. The energetic catastrophe caused by simultaneous interference with glycolysis and oxidative phosphorylation led to cell death or the induction of senescence in tumor cells, with the latter being completely eliminated by senolytics. The occurrence of high synergy upon inhibitor cotreatment was also tested on human colorectal cancer organoids and 119 different tumor cell lines. These experiments revealed highly synergistic activity of the compounds in one third of the tested tumor cell lines, which show statistically significant correlations with alterations in genes with known roles in metabolic regulation.

2025-05-08 | GSE285726 | GEO

Immunogenetic metabolomics revealed key enzymes that modulate CAR-T metabolism and function

Project description:Immunogenetic metabolomics revealed key enzymes that modulate CAR-T metabolism and function

| PRJNA934314 | ENA

Correlation of the expression of the key enzymes and the yield of the lipid

Project description:Characterization of the expression of the key enzymes during the growth of Chlorella minutissima UTEX2341

2016-11-13 | GSE63240 | GEO

The ROS Regulates NCF2, Key Metabolic Enzymes and MDA Levels to Affect the Growth of Fusarium solani

Project description:The ROS Regulates NCF2, Key Metabolic Enzymes and MDA Levels to Affect the Growth of Fusarium solani

| PRJNA860073 | ENA

Immunogenetic metabolomics revealed key enzymes that modulate CAR-T metabolism and function [DNA-edit]

Project description:Immunogenetic metabolomics revealed key enzymes that modulate CAR-T metabolism and function [DNA-edit]

| PRJNA934483 | ENA

Immunogenetic metabolomics revealed key enzymes that modulate CAR-T metabolism and function [RNA-seq]

Project description:Immunogenetic metabolomics revealed key enzymes that modulate CAR-T metabolism and function [RNA-seq]

| PRJNA934482 | ENA

Simultaneous targeting of peripheral and brain tumors with a therapeutic nanoparticle to disrupt metabolic adaptability at both sites

Project description:Brain metastasis of advanced breast cancer often results in deleterious consequences. Metastases to the brain lead to significant challenges in treatment options, as the blood– brain barrier (BBB) prevents conventional therapy. Thus, we hypothesized that creation of a nanoparticle (NP) that distributes to both primary tumor site and across the BBB for secondary brain tumor can be extremely beneficial. Here, we report a simple target- ing strategy to attack both the primary breast and secondary brain tumors utilizing a single NP platform. The nature of these mitochondrion-targeted, BBB-penetrating NPs allow for simultaneous targeting and drug delivery to the hyperpolarized mitochondrial membrane of the extracranial primary tumor site in addition to tumors at the brain. By utilizing a combination of such dual anatomical distributing NPs loaded with therapeu- tics, we demonstrate a proof-of-concept idea to combat the increased metabolic plasticity of brain metastases by lowering two major energy sources, oxidative phosphorylation (OXPHOS) and glycolysis. By utilizing complementary studies and genomic analyses, we demonstrate the utility of a chemotherapeutic prodrug to decrease OXPHOS and glycolysis by pairing with a NP loaded with pyruvate dehydrogenase kinase 1 inhibitor. Decreasing glycolysis aims to combat the metabolic flexibility of both primary and sec- ondary tumors for therapeutic outcome. We also address the in vivo safety parameters by addressing peripheral neuropathy and neurobehavior outcomes. Our results also demonstrate that this combination therapeutic approach utilizes mitochondrial genome targeting strategy to overcome DNA repair–based chemoresistance mechanisms.

2024-04-26 | GSE264575 | GEO

Targeting Valine Catabolism for Selective Inhibition of Metabolic Reprogramming in Prostate Cancer

Project description:Metabolic reprogramming and energetic rewiring are hallmarks of cancer which fuel disease progression and facilitate evasion to the rising anti-tumour pressures introduced by therapy. The remodelling of oxidative phosphorylation and enhanced lipogenesis have previously been characterised as key metabolic features of prostate cancer (PCa). Recently, succinate-dependent mitochondrial reprogramming was identified in high-grade PCa tumours, as well as upregulation of the enzymes associated with branched-chain amino acid (BCAA) catabolism. In this study, we hypothesised that the degradation of the BCAAs, particularly valine, may play a critical role in anapleurotic refuelling of the mitochondrial succinate pool, as well as the maintenance of intracellular lipids in PCa.

2024-01-18 | GSE253413 | GEO

Simultaneous targeting of peripheral and brain tumors with a therapeutic nanoparticle to disrupt metabolic adaptability at both sites

Project description:Simultaneous targeting of peripheral and brain tumors with a therapeutic nanoparticle to disrupt metabolic adaptability at both sites

| PRJNA1103175 | ENA

Targeting of non-phosphorylated lysosomal enzymes involves secretion and Lrp1-mediated recapture

Project description:Most lysosomal enzymes require mannose 6-phosphate (M6P) residues for efficient receptor-mediated lysosomal targeting. Although the lack of M6P results in missorting and hypersecretion, selected lysosomal enzymes reach normal levels in lysosomes of various cell types suggesting the existence of M6P-independent transport routes. SILAC-based analysis of purified lysosomes from M6P-deficient mouse fibroblasts (PTki) revealed unchanged amounts of 11 lysosomal enzymes, including cathepsin D and B (CtsD, CtsB), while demonstrating mossiorting of a variety of soluble lysosomal enzymes

2015-05-01 | PXD001221 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data